EADO overview of last four years achievements in immunotherapy: ipilimumab, nivolumab and pembrolizumab. Good to see again the confirmation of their efficacy in melanoma.
(to be continued)
Wednesday, 28 October 2015
Today has started Melanoma QuickStart pre-EADO workshop organized by MPNE and Melanome France around EADO conference.
I was glad to meet there
Gilliosa Spurrier (Melanome France), Fredrik Östman (Sweden), Gislaine Cramers (Stichting Melanoom, Netherlands), Antonella Romanini (ACM, Italy), Anca Andronic (Melanom Romania), Kacie King (Belgium), Henriette Sandven (Norway),Corinne Forest (France), Debora Podestà (Italy), Gudrun Uthaug (Norway) and Martina Kiehl (Germany).
In total 15 patients, carers and patients advocates from different countries participated to the workshop and will attend EADO Congress in Marseille (28-31 october), learning about the new treatments landscape in melanoma and how to share the information with their own national groups.
Interestingly for patients on pembrolizumab, vitiligo (white spots on the skin) seems to indicate a positive response of the drug. Good news to me at least :)
Caroline Roberts put it very cautiously that "at least it is not very bad [for the patients]" at EADO 2015.
Even though the dataset was small (N = 67), out of the 17 people who got vitiligo only two of them had a progressive decease. But the rest were either stable (3), or had partial (9) or complete (3) regression. So if you get vitiligo it might mean good news, but a larger dataset is needed to show if it is statistically significant.
Patients must be prepared to lobby HTA and Reimbursement authorities as they frequently do not listen to Expert opinions, which leads to decisions that are NOT in the interest of Patients - Melanoma Patients are often well-informed ..
Tuesday, 20 October 2015
SO - WHO ARE THE STAKEHOLDERS IN MELANOMA TREATMENT/TRIALS ?
What is a stakeholder ?
A group of people with shared interests that are different from other groups
Clearly the most important stakeholders are those who commit their lives :
Then we have : CARERS and FAMILIES
also GOVERNMENTS who bear the costs of healthcare
then we have CLINICIANS and RESEARCHERS who do the work
we have the PHARMACEUTICAL COMPANIES who fund development
we have HEALTH TECHNOLOGY ASSESSORS who decide on the risks/benefits
we have THE PUBLIC